EN
Instrument Fundamentals
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
News
Has Novavax (NVAX) Fallen Far Enough To Look Cheap?
FDA Approves Seasonal Covid-19 Vaccines From Moderna, Pfizer, BioNTech, Novavax - Update | Morningstar
Novavax partners secure Nuvaxovid approvals for 2026-2027 season
Novavax's XFG-Adapted Nuvaxovid Approved In U.S., EU, Japan For 2026-2027 Season
Novavax Partners Receive Approvals For Nuvaxovid Formulation To Target Covid Variant
Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season | Morningstar
Zacks Research Has Negative Outlook for Novavax Q3 Earnings
Novavax Stock Pulls Back After Milestone Vaccine Success
Traders Purchase Large Volume of Put Options on Novavax (NASDAQ:NVAX)
Unpacking Q2 Earnings: Novavax (NASDAQ:NVAX) In The Context Of Other Therapeutics Stocks
Novavax (NASDAQ:NVAX) Trading Down 6.8% - Time to Sell? - Zolmax
NVAX Stock Alert: Biotechs Hit Post-Pandemic High on mRNA Cancer Breakthrough
Novavax (NASDAQ:NVAX) Trading Up 6.9% - Still a Buy?
Novavax (NASDAQ:NVAX) Shares Up 6.9% - Here's Why - Zolmax
Novavax (NASDAQ:NVAX) Stock Price Down 6.8% - What's Next?
Novavax (NVAX) Shares Skyrocket, What You Need To Know
Investors Buy Large Volume of Call Options on Novavax (NASDAQ:NVAX)
Traders Purchase Large Volume of Call Options on Novavax (NASDAQ:NVAX) - Stock Observer
Novavax, Inc. (NASDAQ:NVAX) Given Consensus Rating of "Hold" by Analysts
Bank of America Corp DE Cuts Stock Holdings in Novavax, Inc. $NVAX
Novavax (NASDAQ:NVAX) Lowered to Hold Rating by Zacks Research
NVAX Q2 Earnings & Sales Beat Estimates, '26 Sales Outlook Raised
Novavax Boosts Revenue Outlook Amid Vaccine Demand Challenges, ETPharma
Novavax Q2 Earnings Call Highlights
Novavax (NASDAQ:NVAX) Posts Earnings Results, Beats Estimates By $0.06 EPS
Novavax Inc (NVAX) (Q2 2026) Earnings Call Highlights: Matrix-M Momentum Drives Revenue ...
Novavax Slips To Loss In Q2 On Reduced Revenue, Cuts FY26 Guidance
Novavax (NASDAQ:NVAX) Exceeds Q2 CY2026 Expectations
Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights | Morningstar
Novavax lifts annual revenue forecast as licensing bets offset weak vaccine demand
NVAX Stock Rises Ahead Of Q2 Earnings As Focus Shifts To Licensing Deals
